After establishing dosing and safety in Phase I, researchers will evaluate the drug's anti-tumor activity in patients with PSMA-expressing cancers.

DCx sees potential to build multifunctional ADCs using the same technology Repare used to create its small molecule synthetic lethal therapies.

The firm is studying the combination in the first-line setting for head and neck cancer patients who had a PD-L1 combined positive score of less than 1.

The biotech has nominated MB-111, a drug it's developing as a treatment for elevated triglycerides, as its first clinical development candidate.

Researchers at AACR discussed what's next for the drug class, given the disappointing activity of tiragolumab with Tecentriq ...

Cancer patients invariably develop resistance to targeted drugs, so drugmakers develop strategies to combat it before ...

Biotech firms are engineering smarter, safer gene delivery systems to enhance the safety and efficacy of genetic medicines.

The company said it took financial hits from the Inflation Reduction Act's Medicare Part D redesign, which included higher ...

The New York-based public benefit corporation is advancing three drug candidates for the extremely rare condition.

DCx will gain rights to technology, targets, and preclinical programs from Repare along with lab space and staff in Montreal.

The nonprofit says its pipeline offers more affordable and accessible therapeutics, including point-of-care CAR-T cell therapy for leukemia and lymphoma.